EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
Michael Dell Pledges $6.25 Billion to Boost Children’s Investment Accounts Under Trump Initiative 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Netflix Nearing Major Deal to Acquire Warner Bros Discovery Assets 
Airline Loyalty Programs Face New Uncertainty as Visa–Mastercard Fee Settlement Evolves 
UPS MD-11 Crash Prompts Families to Prepare Wrongful Death Lawsuit 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
Magnum Audit Flags Governance Issues at Ben & Jerry’s Foundation Ahead of Spin-Off 
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
Visa to Move European Headquarters to London’s Canary Wharf 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
USPS Expands Electric Vehicle Fleet as Nationwide Transition Accelerates 
BOSTON, Dec. 01, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, today announced it will present at the Oppenheimer & Co., Inc. 26th Annual Healthcare Conference in New York City on December 8, 2015 at 9:45 a.m. EST.
A live audio webcast of the presentation will be accessible from Keryx’s website at http://investors.keryx.com within the Investor Relations section under the “webcasts and presentations” page. An archived version of the webcast will be available for at least 15 days following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, with offices in Boston and New York, is focused on bringing innovative therapies to market for patients with renal disease. In December 2014, the company launched its first FDA-approved product, Auryxia™ (ferric citrate) for the control of elevated serum phosphorus levels, or hyperphosphatemia, in patients with chronic kidney disease (CKD) on dialysis, in the United States. In January 2014, ferric citrate was approved for the treatment of patients with all stages of CKD in Japan, where it is being marketed as Riona® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex) for the control of hyperphosphatemia in adults with non-dialysis and dialysis-dependent chronic kidney disease. For more information about Keryx, please visit www.keryx.com.
KERYX CONTACT: Lora Pike Senior Director, Investor Relations T: 617-466-3511 [email protected]
